{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:51:34Z","timestamp":1787071894188,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0504000"],"award-info":[{"award-number":["2023ZD0504000"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2024-I2M-C&T-B-040"],"award-info":[{"award-number":["2024-I2M-C&T-B-040"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2024-I2M-ZH-004"],"award-info":[{"award-number":["2024-I2M-ZH-004"]}]},{"name":"Artificial Intelligence and Information Technology Application Fund of Fuwai Hospital and Chinese Academy of Medical Sciences","award":["2024-AI22"],"award-info":[{"award-number":["2024-AI22"]}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["2024-GSP-GG-4"],"award-info":[{"award-number":["2024-GSP-GG-4"]}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["2025-GSP-GG-14"],"award-info":[{"award-number":["2025-GSP-GG-14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Secondary prevention of coronary heart disease (CHD) remains suboptimal due to fragmented care and therapeutic inertia. While digital health interventions offer a promising strategy, few existing tools provide comprehensive, closed-loop management of multidimensional risk factors without increasing clinician workload. This study aimed to evaluate the efficacy of an artificial intelligence (AI)\u2013enhanced management system (AIM-CHD) in improving multidimensional risk factor control among patients with CHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single-center, open-label, parallel-group, randomized clinical trial was conducted from November 2024 to June 2025 in China. A total of 1100 adults with confirmed CHD were randomized 1:1 to receive either the AIM-CHD intervention (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009549) or usual care (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009551) for 3 months. The AIM-CHD system featured automated multi-source data capture, guideline-directed risk stratification, and closed-loop feedback via smartphone. The primary outcome was the low-density lipoprotein cholesterol (LDL-C) level at 3 months. Secondary outcomes included goal attainment rates for LDL-C (&lt;\u200970\u00a0mg\/dL) and blood pressure (BP, &lt;\u2009130\/80\u00a0mm Hg), glycated hemoglobin, smoking cessation, body mass index (BMI), medication adherence, and a composite cardiovascular endpoint at 3 months. Analysis was performed on an intention-to-treat (ITT) basis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1100 randomized participants (mean age 61 years; 75.3% male), 943 (85.7%) completed the 3-month follow-up. The intervention group achieved a significantly lower mean LDL-C level compared with the control group (60.4\u2009\u00b1\u200923.4 vs. 63.7\u2009\u00b1\u200926.0\u00a0mg\/dL), with an adjusted mean difference of \u2212\u20093.2\u00a0mg\/dL (95% CI, \u2212\u20096.2 to \u2212\u20090.3;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). Furthermore, participants in the intervention group were more likely to achieve the LDL-C target (71% vs. 64%; RR, 1.10; 95% CI, 1.01\u20131.20;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) and the BP target (45% vs. 35%; RR, 1.27; 95% CI, 1.09\u20131.48;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). No significant differences were observed for HbA1c, BMI, or medication adherence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The AIM-CHD system significantly improved short-term lipid and BP control compared with usual care. These findings support interoperable, low-burden digital management systems as a scalable strategy in routine secondary prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT06686056. Registered on 11 November 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-05135-w","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:03:51Z","timestamp":1787069031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Artificial intelligence\u2013enhanced management system for secondary prevention of coronary heart disease: a randomized clinical trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhengqing","family":"Ba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanshu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"22","key":"5135_CR1","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","volume":"86","author":"Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators","year":"2025","unstructured":"Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990\u20132023. J Am Coll Cardiol. 2025;86(22):2167\u2013243. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.015.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"5135_CR2","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9\u2013119. https:\/\/doi.org\/10.1161\/CIR.0000000000001168.","journal-title":"Circulation"},{"issue":"7","key":"5135_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3760\/cma.j.cn112148-20250422-00302","volume":"53","author":"Chinese Society of Cardiology, Chinese Medical Association","year":"2025","unstructured":"Chinese Society of Cardiology, Chinese Medical Association. Editorial Board of Chinese Journal of Cardiology. [Guidelines for percutaneous coronary intervention (2025)]. Zhonghua xin xue guan bing za zhi. 2025;53(7):717\u201345. https:\/\/doi.org\/10.3760\/cma.j.cn112148-20250422-00302.","journal-title":"Zhonghua xin xue guan bing za zhi"},{"issue":"8","key":"5135_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","volume":"26","author":"K Kotseva","year":"2019","unstructured":"Kotseva K, De Backer G, De Bacquer D, Ryd\u00e9n L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824\u201335. https:\/\/doi.org\/10.1177\/2047487318825350.","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"5135_CR5","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2021.1810.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"5135_CR6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1161\/HYPERTENSIONAHA.120.15866","volume":"77","author":"A Augustin","year":"2021","unstructured":"Augustin A, Coutts L, Zanisi L, Wierzbicki AS, Shankar F, Chowienczyk PJ, et al. Impact of therapeutic inertia on long-term blood pressure control: a Monte Carlo simulation study. Hypertension. 2021;77(4):1350\u20139. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15866.","journal-title":"Hypertension"},{"issue":"1","key":"5135_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5334\/gh.1278","volume":"19","author":"L Laranjo","year":"2024","unstructured":"Laranjo L, Lanas F, Sun MC, Chen DA, Hynes L, Imran TF, et al. World Heart Federation roadmap for secondary prevention of cardiovascular disease: 2023 update. Glob Heart. 2024;19(1):8. https:\/\/doi.org\/10.5334\/gh.1278.","journal-title":"Glob Heart"},{"issue":"7","key":"5135_CR8","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1016\/S2589-7500(19)30151-7","volume":"1","author":"T Dorje","year":"2019","unstructured":"Dorje T, Zhao G, Tso K, Wang J, Chen Y, Tsokey L, et al. Smartphone and social media-based cardiac rehabilitation and secondary prevention in China (SMART-CR\/SP): a parallel-group, single-blind, randomised controlled trial. Lancet Digit Health. 2019;1(7):e363\u201374. https:\/\/doi.org\/10.1016\/S2589-7500(19)30151-7.","journal-title":"Lancet Digit Health"},{"key":"5135_CR9","doi-asserted-by":"publisher","first-page":"e55421","DOI":"10.2196\/55421","volume":"12","author":"C Cruz-Cobo","year":"2024","unstructured":"Cruz-Cobo C, Bernal-Jim\u00e9nez M\u00c1, Calle G, Gheorghe LL, Guti\u00e9rrez-Barrios A, Ca\u00f1adas D, et al. Efficacy of a mobile health app (eMOTIVA) regarding compliance with cardiac rehabilitation guidelines in patients with coronary artery disease: randomized controlled clinical trial. JMIR Mhealth Uhealth. 2024;12:e55421. https:\/\/doi.org\/10.2196\/55421.","journal-title":"JMIR Mhealth Uhealth"},{"key":"5135_CR10","doi-asserted-by":"publisher","first-page":"e48756","DOI":"10.2196\/48756","volume":"12","author":"M\u00c1 Bernal-Jim\u00e9nez","year":"2024","unstructured":"Bernal-Jim\u00e9nez M\u00c1, Calle G, Guti\u00e9rrez Barrios A, Gheorghe LL, Cruz-Cobo C, Trujillo-Garrido N, et al. Effectiveness of an interactive mHealth app (EVITE) in improving lifestyle after a coronary event: randomized controlled trial. JMIR Mhealth Uhealth. 2024;12:e48756. https:\/\/doi.org\/10.2196\/48756.","journal-title":"JMIR Mhealth Uhealth"},{"issue":"1","key":"5135_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ehjdh\/ztac069","volume":"4","author":"R Gallagher","year":"2023","unstructured":"Gallagher R, Chow CK, Parker H, Neubeck L, Celermajer DS, Redfern J, et al. The effect of a game-based mobile app MyHeartMate to promote lifestyle change in coronary disease patients: a randomized controlled trial. Eur Heart J Digit Health. 2023;4(1):33\u201342. https:\/\/doi.org\/10.1093\/ehjdh\/ztac069.","journal-title":"Eur Heart J Digit Health"},{"issue":"9","key":"5135_CR12","doi-asserted-by":"publisher","first-page":"e29928","DOI":"10.2196\/29928","volume":"9","author":"JW Bae","year":"2021","unstructured":"Bae JW, Woo SI, Lee J, Park SD, Kwon SW, Choi SH, et al. mHealth interventions for lifestyle and risk factor modification in coronary heart disease: randomized controlled trial. JMIR Mhealth Uhealth. 2021;9(9):e29928. https:\/\/doi.org\/10.2196\/29928.","journal-title":"JMIR Mhealth Uhealth"},{"issue":"12","key":"5135_CR13","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jama.2015.10945","volume":"314","author":"CK Chow","year":"2015","unstructured":"Chow CK, Redfern J, Hillis GS, Thakkar J, Santo K, Hackett ML, et al. Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial. JAMA. 2015;314(12):1255\u201363. https:\/\/doi.org\/10.1001\/jama.2015.10945.","journal-title":"JAMA"},{"issue":"1","key":"5135_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13643-025-02857-5","volume":"14","author":"SM Abate","year":"2025","unstructured":"Abate SM, Thanigaimani S, Sinha M, Sun D, Golledge J. A systematic review and meta-analysis testing the effect of lifestyle modification and medication optimization programs on cholesterol and blood pressure in patients with cardiovascular disease. Syst Rev. 2025;14(1):153. https:\/\/doi.org\/10.1186\/s13643-025-02857-5.","journal-title":"Syst Rev"},{"issue":"9","key":"5135_CR15","doi-asserted-by":"publisher","first-page":"e676","DOI":"10.1016\/S2589-7500(22)00124-8","volume":"4","author":"PX Kuan","year":"2022","unstructured":"Kuan PX, Chan WK, Fern Ying DK, Abdul Rahman MA, Peariasamy KM, Lai NM, et al. Efficacy of telemedicine for the management of cardiovascular disease: a systematic review and meta-analysis. Lancet Digit Health. 2022;4(9):e676\u201391. https:\/\/doi.org\/10.1016\/S2589-7500(22)00124-8.","journal-title":"Lancet Digit Health"},{"issue":"19","key":"5135_CR16","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1161\/CIRCULATIONAHA.121.056161","volume":"145","author":"CK Chow","year":"2022","unstructured":"Chow CK, Klimis H, Thiagalingam A, Redfern J, Hillis GS, Brieger D, et al. Text messages to improve medication adherence and secondary prevention after acute coronary syndrome: the TEXTMEDS randomized clinical trial. Circulation. 2022;145(19):1443\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056161.","journal-title":"Circulation"},{"key":"5135_CR17","doi-asserted-by":"publisher","first-page":"e38275","DOI":"10.2196\/38275","volume":"25","author":"NW Cheung","year":"2023","unstructured":"Cheung NW, Redfern J, Thiagalingam A, Hng TM, Marschner S, Haider R, et al. Effect of mobile phone text messaging self-management support for patients with diabetes or coronary heart disease in a chronic disease management program (SupportMe) on blood pressure: pragmatic randomized controlled trial. J Med Internet Res. 2023;25:e38275. https:\/\/doi.org\/10.2196\/38275.","journal-title":"J Med Internet Res"},{"issue":"4","key":"5135_CR18","doi-asserted-by":"publisher","first-page":"e005616","DOI":"10.1161\/CIRCOUTCOMES.119.005616","volume":"12","author":"X Zheng","year":"2019","unstructured":"Zheng X, Spatz ES, Bai X, Huo X, Ding Q, Horak P, et al. Effect of text messaging on risk factor management in patients with coronary heart disease: the CHAT randomized clinical trial. Circ Cardiovasc Qual Outcomes. 2019;12(4):e005616. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.119.005616.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"23","key":"5135_CR19","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1016\/j.jacc.2024.03.398","volume":"83","author":"NS Alshahrani","year":"2024","unstructured":"Alshahrani NS, Hartley A, Howard J, Hajhosseiny R, Khawaja S, Seligman H, et al. Randomized trial of remote assessment of patients after an acute coronary syndrome. J Am Coll Cardiol. 2024;83(23):2250\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.398.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"5135_CR20","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/s41591-025-03498-w","volume":"31","author":"S Mueller","year":"2025","unstructured":"Mueller S, Dinges SMT, Gass F, Fegers-Wustrow I, Treitschke J, von Korn P, et al. Telemedicine-supported lifestyle intervention for glycemic control in patients with CHD and T2DM: multicenter, randomized controlled trial. Nat Med. 2025;31(4):1203\u201313. https:\/\/doi.org\/10.1038\/s41591-025-03498-w.","journal-title":"Nat Med"},{"issue":"1","key":"5135_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41746-025-01655-6","volume":"8","author":"L Yang","year":"2025","unstructured":"Yang L, Wang Z, Zhao S, Liu M, Zhu Y, Hu F, et al. Effectiveness of digital healthcare to improve clinical outcomes in discharged patients with coronary artery disease. NPJ Digit Med. 2025;8(1):473. https:\/\/doi.org\/10.1038\/s41746-025-01655-6.","journal-title":"NPJ Digit Med"},{"issue":"2","key":"5135_CR22","doi-asserted-by":"publisher","first-page":"e32251","DOI":"10.2196\/32251","volume":"10","author":"Y Li","year":"2022","unstructured":"Li Y, Gong Y, Zheng B, Fan F, Yi T, Zheng Y, et al. Effects on adherence to a mobile app-based self-management digital therapeutics among patients with coronary heart disease: pilot randomized controlled trial. JMIR Mhealth Uhealth. 2022;10(2):e32251. https:\/\/doi.org\/10.2196\/32251.","journal-title":"JMIR Mhealth Uhealth"},{"issue":"9","key":"5135_CR23","doi-asserted-by":"publisher","first-page":"e105597","DOI":"10.1136\/bmjopen-2025-105597","volume":"15","author":"Z Ba","year":"2025","unstructured":"Ba Z, Zhao S, Liu M, Chen G, Lian X, Yu F, et al. Effectiveness of an AI-enhanced management system for coronary heart disease (AIM-CHD): rationale and design of a single-centre, open-label, randomised, parallel-controlled trial. BMJ Open. 2025;15(9):e105597. https:\/\/doi.org\/10.1136\/bmjopen-2025-105597.","journal-title":"BMJ Open"},{"key":"5135_CR24","doi-asserted-by":"publisher","first-page":"1502990","DOI":"10.3389\/fdgth.2025.1502990","volume":"7","author":"C Pongchaiyakul","year":"2025","unstructured":"Pongchaiyakul C, Driessen S. Evaluating the effect of mobile applications My A:Care and Smart Coach on adherence to lipid-lowering treatment in patients with dyslipidemia: a prospective, randomized, open-label clinical study. Front Digit Health. 2025;7:1502990. https:\/\/doi.org\/10.3389\/fdgth.2025.1502990.","journal-title":"Front Digit Health"},{"issue":"9","key":"5135_CR25","doi-asserted-by":"publisher","first-page":"e2529762","DOI":"10.1001\/jamanetworkopen.2025.29762","volume":"8","author":"PZ Zhang","year":"2025","unstructured":"Zhang PZ, Guo D, Liu CQ, Chen N, Liu JF, Lei XZ, et al. Mobile app-based intervention and cardiovascular risk factors in patients with uncontrolled type 2 diabetes: a randomized clinical trial. JAMA Netw Open. 2025;8(9):e2529762. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.29762.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"5135_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/heartjnl-2018-313479","volume":"105","author":"K Santo","year":"2019","unstructured":"Santo K, Singleton A, Rogers K, Thiagalingam A, Chalmers J, Chow CK, et al. Medication reminder applications to improve adherence in coronary heart disease: a randomised clinical trial. Heart. 2019;105(4):323\u20139. https:\/\/doi.org\/10.1136\/heartjnl-2018-313479.","journal-title":"Heart"},{"issue":"8","key":"5135_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/1357633X19885793","volume":"27","author":"JA Snoek","year":"2021","unstructured":"Snoek JA, Meindersma EP, Prins LF, van\u2019t Hof AWJ, de Boer MJ, Hopman MT, et al. The sustained effects of extending cardiac rehabilitation with a six-month telemonitoring and telecoaching programme on fitness, quality of life, cardiovascular risk factors and care utilisation in CAD patients: the TeleCaRe study. J Telemed Telecare. 2021;27(8):473\u201383. https:\/\/doi.org\/10.1177\/1357633X19885793.","journal-title":"J Telemed Telecare"},{"issue":"1","key":"5135_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1001\/jamacardio.2022.4018","volume":"8","author":"AJ Blood","year":"2023","unstructured":"Blood AJ, Cannon CP, Gordon WJ, Mailly C, MacLean T, Subramaniam S, et al. Results of a remotely delivered hypertension and lipid program in more than 10 000 patients across a diverse health care network. JAMA Cardiol. 2023;8(1):12\u201321. https:\/\/doi.org\/10.1001\/jamacardio.2022.4018.","journal-title":"JAMA Cardiol"},{"key":"5135_CR29","volume-title":"Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. Geneva: World Health Organization; 2011."},{"issue":"25 Suppl 2","key":"5135_CR30","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1161\/01.CIR.0000437739.71477.EE","volume":"129","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102\u201338. https:\/\/doi.org\/10.1161\/01.CIR.0000437739.71477.EE.","journal-title":"Circulation"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05135-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05135-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05135-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:03:55Z","timestamp":1787069035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05135-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5135"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05135-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (approval No. 2024\u20132422), and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"449"}}